These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 22339911)
1. [Outcome of acute promyelocytic leukemia with homoharringtonine (HHT) and ATRA]. Yuan Y; Li W; Lin D; Mi YC; Wang Y; Wei H; Liu BC; Zhou CL; Liu KQ; Wang JY; Wei SN; Gong BF; Zhao XL; Sun MY; Wan JX Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):752-7. PubMed ID: 22339911 [TBL] [Abstract][Full Text] [Related]
2. [Homoharringtonine in newly diagnosed acute promyelocytic leukemia treatment: a prospective, randomized controlled trial]. Wang Y; Liu BC; Wei H; Lin D; Zhou CL; Liu KQ; Li W; Wei SN; Wang JY; Gong BF; Zhang GJ; Zhao XL; Liu YT; Gong XY; Li Y; Gu RX; Mi YC; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):183-8. PubMed ID: 27033753 [TBL] [Abstract][Full Text] [Related]
3. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia]. Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073 [TBL] [Abstract][Full Text] [Related]
4. [Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia]. Pei RZ; Li SY; Zhang PS; Ma JX; Liu XH; Du XH; Chen D; Sha KY; Chen LG; Cao JJ; Zhuang XX; Wu JY; Lin L; Fan Z; Ye PP; Tang SH; Zhang BB; Shi XW Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):144-8. PubMed ID: 23611222 [TBL] [Abstract][Full Text] [Related]
5. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370 [TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Sakamaki H; Tsubaki K; Saito K; Ohno R Cancer Chemother Pharmacol; 1997; 40 Suppl():S30-5. PubMed ID: 9272131 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of homoharringtonine plus all-trans retinoic acid-based induction and consolidation therapy in newly diagnosed acute promyelocytic leukemia. Wang Y; Lin D; Wei H; Li W; Liu B; Zhou C; Liu K; Mi Y; Wang J Int J Hematol; 2015 Mar; 101(3):279-85. PubMed ID: 25563706 [TBL] [Abstract][Full Text] [Related]
8. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687 [TBL] [Abstract][Full Text] [Related]
9. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250 [TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Fenaux P; Chastang C; Chevret S; Sanz M; Dombret H; Archimbaud E; Fey M; Rayon C; Huguet F; Sotto JJ; Gardin C; Makhoul PC; Travade P; Solary E; Fegueux N; Bordessoule D; Miguel JS; Link H; Desablens B; Stamatoullas A; Deconinck E; Maloisel F; Castaigne S; Preudhomme C; Degos L Blood; 1999 Aug; 94(4):1192-200. PubMed ID: 10438706 [TBL] [Abstract][Full Text] [Related]
11. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Fenaux P; Castaigne S; Dombret H; Archimbaud E; Duarte M; Morel P; Lamy T; Tilly H; Guerci A; Maloisel F Blood; 1992 Nov; 80(9):2176-81. PubMed ID: 1421389 [TBL] [Abstract][Full Text] [Related]
12. Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis. Li X; Wang C; Chen G; Ji B; Xu Y Hematology; 2017 Sep; 22(8):450-459. PubMed ID: 28480800 [TBL] [Abstract][Full Text] [Related]
13. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. Head DR; Kopecky KJ; Willman C; Appelbaum FR Leukemia; 1994; 8 Suppl 2():S38-41. PubMed ID: 7815835 [TBL] [Abstract][Full Text] [Related]
14. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734 [TBL] [Abstract][Full Text] [Related]
16. Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia. Zhu HH; Qin YZ; Lai YY; Shi HX; Liu YR; Jiang B; Huang XJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):872-8. PubMed ID: 23998577 [TBL] [Abstract][Full Text] [Related]